All In Biotech

NDA 021641 · Teva

Azilect

Rasagiline Mesylate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Jun 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

May 16, 2006

Approved uses

3

Original approval plus efficacy supplements

Registered trials

55

19 Phase 3, 0 recruiting

FAERS reports

11,264

7,507 serious, 1,255 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 30, 2020.

AZILECT (rasagiline tablets) is indicated for the treatment of Parkinson’s disease (PD). AZILECT, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson’s disease ( 1 )

Mechanism: AZILECT is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson’s disease. The results of a clinical trial designed to examine the effects of AZILECT on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of AZILECT. The selectivity for inhibiting MAO-B diminishes in a dose-related manner. MAO, a flavin-containing enzyme, is classified into two major molecular species, A and B, and is...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • AZILECT · RASAGILINE MESYLATE EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB
  • AZILECT · RASAGILINE MESYLATE EQ 0.5MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Rasagiline" as an intervention, any sponsor and status, largest first.

All 55 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fall1,093
  • hallucination986
  • dyskinesia784
  • drug ineffective772
  • dizziness675
  • tremor663
  • death638
  • confusional state561
  • parkinson^s disease543
  • gait disturbance536
  • somnolence515
  • nausea501

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20067
200766
2008138
200995
2010271
2011268
2012303
2013437
2014423
2015590
2016692
2017897
2018912
20191,045
20201,057
2021911
2022813
2023521
2024629
2025634
2026555

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Azilect (Rasagiline Mesylate)

2024 spending

$1.4M

Beneficiaries

143

725 claims

Per beneficiary

$9,734

$36.27 per unit

View as table
YearSpending
2020$4,330,711
2021$3,058,965
2022$2,670,658
2023$1,922,416
2024$1,391,907

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 107 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.